StonvexLoading…
StonvexStonvexStonvexCore line items from RXT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.69B | $2.74B | $2.96B | $3.12B |
Operating Income | $-100.70M | $-909.10M | $-899.40M | $-679.00M |
Net Income | $-225.80M | $-858.20M | $-837.80M | $-804.80M |
EPS (Diluted) | $-0.95 | $-3.82 | $-3.89 | $-3.81 |
Total Assets | $2.80B | $3.05B | $4.10B | $5.46B |
Total Liabilities | $4.02B | $4.06B | $4.25B | $4.83B |
Cash & Equivalents | $105.80M | $144.00M | $196.80M | $228.40M |
Free Cash Flow OCF − CapEx | $90.60M | $-71.20M | $278.00M | $166.30M |
Shares Outstanding | 245.30M | 229.10M | 217.40M | 212.60M |